The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Shohan et al.,
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A..,
European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.1746158
Small RCT with 60 severe hospitalized patients in Iran, 30 treated with quercetin, showing shorter time until discharge. All patients received remdesivir or favipiravir, and vitamin C, vitamin D, famotidine, zinc, dexamethasone, and magnesium (depending on serum levels). Quercetin 1000mg daily for 7 days. IRCT20200419047128N2.
risk of death, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.71, treatment 3 of 30 (10.0%), control 5 of 30 (16.7%), NNT 15.
|
time to discharge from end of intervention, 32.4% lower, relative time 0.68, p = 0.04, treatment 30, control 30.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Shohan et al., 2 Dec 2021, Randomized Controlled Trial, Iran, peer-reviewed, mean age 50.9 (treatment) 52.7 (control), 8 authors, average treatment delay 7.8 days.
Contact:
akhodadadi2@gmail.com, akhodadadi@ajums.ac.ir.
Abstract: Journal Pre-proof
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized
COVID-19 patients: A randomized controlled trial
Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad
Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Ali
Khodadadi
PII:
S0014-2999(21)00771-8
DOI:
https://doi.org/10.1016/j.ejphar.2021.174615
Reference:
EJP 174615
To appear in:
European Journal of Pharmacology
Received Date: 18 June 2021
Revised Date:
23 October 2021
Accepted Date: 1 November 2021
Please cite this article as: Shohan, M., Nashibi, R., Mahmoudian-Sani, M.-R., Abolnezhadian, F.,
Ghafourian, M., Alavi, S.M., Sharhani, A., Khodadadi, A., The therapeutic efficacy of quercetin in
combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial,
European Journal of Pharmacology (2022), doi: https://doi.org/10.1016/j.ejphar.2021.174615.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier B.V.
Authorship contribution statement
Mojtaba Shohan: Conceptualization, Methodology, Writing original draft, Writing – review and editing.
Roohangiz Nashibi: Visualization, Supervision. Mohammad-Reza Mahmoudian-Sani: Methodology,
Investigation.
Farhad
Abolnezhadian:
Supervision.
Mehri
Ghafourian:
Review
and
editing.
Seyed Mohammad Alavi: Supervision. Asaad Sharhani: Formal analysis, Visualization. Ali Khodadadi:
Jo
ur
na
lP
re
-p
ro
of
Supervision, Conceptualization, Funding acquisition.
And The therapeutic efficacy of quercetin in combination with antiviral drugs
in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan a,b , Roohangiz Nashibi c , Mohammad-Reza Mahmoudian-Sani
d
Farhad Abolnezhadian e , Mehri Ghafourian a , Seyed Mohammad Alavi c , Asaad Sharhani f , Ali Khodadadi a,g
a Department of Immunology, School of M edicine, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran
b Student Research Committee, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran
of
c Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of M edical
ro
Sciences, Ahvaz, Iran
-p
d Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of M edical
re
Sciences, Ahvaz, Iran
lP
e Department of Pediatrics, Abuzar children's hospital, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran
f Department of Epidemiology and Biostatistics, School of public health, Ahvaz Jundishapur University of M edical Sciences ,
na
Ahvaz, Iran
Jo
ur
g Cancer Research Center, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran
Corresponding author: Dr. Ali Khodadadi, Professor in Immunology
Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences,
Ahvaz, Iran
E-mail Address: akhodadadi2@gmail.com and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit